Sign in or create an account to add this stock to your watchlist.
About IDEXX Laboratories (NASDAQ:IDXX)
IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. The company provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. It also offers diagnostic and health-monitoring products for livestock, poultry, and dairy markets; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryHealth Care Equipment
Trailing P/E Ratio69.48
Forward P/E Ratio54.65
Sales & Book Value
Annual Sales$1.97 billion
Price / Sales10.05
Cash Flow$4.3261 per share
Price / Cash52.68
Book Value($0.62) per share
Price / Book-367.58
EPS (Most Recent Fiscal Year)$3.28
Net Income$263.14 million
Return on Equity-530.24%
Return on Assets19.39%
IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions
What is IDEXX Laboratories' stock symbol?
IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."
How will IDEXX Laboratories' stock buyback program work?
IDEXX Laboratories declared that its board has initiated a share repurchase plan on Sunday, June 4th 2017, which permits the company to repurchase 3,000,000 outstanding shares, according to EventVestor. This repurchase authorization permits the company to buy shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's management believes its shares are undervalued.
How were IDEXX Laboratories' earnings last quarter?
IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted its quarterly earnings results on Friday, May, 4th. The company reported $1.01 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.92 by $0.09. The business had revenue of $537.60 million for the quarter, compared to analyst estimates of $525.14 million. IDEXX Laboratories had a net margin of 13.87% and a negative return on equity of 530.24%. The company's revenue was up 16.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.77 earnings per share. View IDEXX Laboratories' Earnings History.
When is IDEXX Laboratories' next earnings date?
What guidance has IDEXX Laboratories issued on next quarter's earnings?
IDEXX Laboratories issued an update on its FY18 earnings guidance on Friday, May, 4th. The company provided earnings per share (EPS) guidance of $4.06-4.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.11. The company issued revenue guidance of +12-14% to ~$2.205-2.245 billion, compared to the consensus revenue estimate of $2.22 billion.
What price target have analysts set for IDXX?
7 analysts have issued 12 month price objectives for IDEXX Laboratories' stock. Their forecasts range from $200.00 to $228.00. On average, they expect IDEXX Laboratories' stock price to reach $216.50 in the next year. View Analyst Ratings for IDEXX Laboratories.
Who are some of IDEXX Laboratories' key competitors?
Some companies that are related to IDEXX Laboratories include IPSEN S A/S (IPSEY), Neogen (NEOG), Immunomedics (IMMU), Myriad Genetics (MYGN), Quidel (QDEL), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX) and Vermillion (VRML).
Who are IDEXX Laboratories' key executives?
IDEXX Laboratories' management team includes the folowing people:
- Mr. Jonathan W. Ayers, Chairman, CEO & Pres (Age 62)
- Mr. Brian P. McKeon, CFO, Exec. VP & Treasurer (Age 56)
- Ms. Jacqueline L. Studer, Corp. VP, Gen. Counsel & Sec. (Age 59)
- Mr. Giovani Twigge, Chief HR Officer & Corp. VP (Age 54)
- Mr. Jay Mazelsky, Exec. VP (Age 57)
Has IDEXX Laboratories been receiving favorable news coverage?
Press coverage about IDXX stock has trended somewhat positive on Sunday, Accern reports. The research firm identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. IDEXX Laboratories earned a daily sentiment score of 0.11 on Accern's scale. They also assigned media stories about the company an impact score of 46.61 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are IDEXX Laboratories' major shareholders?
IDEXX Laboratories' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.61%), Bamco Inc. NY (5.15%), Blair William & Co. IL (1.87%), Neuberger Berman Group LLC (1.86%), Northern Trust Corp (1.16%) and Old Mutual Global Investors UK Ltd. (1.08%). Company insiders that own IDEXX Laboratories stock include Barry C Johnson, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Lawrence D Kingsley, Michael J Phd Williams, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for IDEXX Laboratories.
Which major investors are selling IDEXX Laboratories stock?
IDXX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Bamco Inc. NY, Blair William & Co. IL, Millennium Management LLC, Federated Investors Inc. PA, Natixis, American Century Companies Inc. and Old Mutual Global Investors UK Ltd.. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Rebecca M Henderson and William T End. View Insider Buying and Selling for IDEXX Laboratories.
Which major investors are buying IDEXX Laboratories stock?
IDXX stock was bought by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, AGF Investments Inc., Prudential Financial Inc., OppenheimerFunds Inc., Westfield Capital Management Co. LP, Wells Fargo & Company MN, Select Equity Group L.P. and Chicago Capital LLC. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.
How do I buy shares of IDEXX Laboratories?
Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IDEXX Laboratories' stock price today?
One share of IDXX stock can currently be purchased for approximately $227.90.
How big of a company is IDEXX Laboratories?
IDEXX Laboratories has a market capitalization of $19.80 billion and generates $1.97 billion in revenue each year. The company earns $263.14 million in net income (profit) each year or $3.28 on an earnings per share basis. IDEXX Laboratories employs 7,600 workers across the globe.
How can I contact IDEXX Laboratories?
IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]
MarketBeat Community Rating for IDEXX Laboratories (IDXX)MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote "Outperform" if you believe IDXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
IDEXX Laboratories (NASDAQ:IDXX) Price Target and Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for IDEXX Laboratories in the last 12 months. Their average twelve-month price target is $216.50, suggesting that the stock has a possible downside of 5.00%. The high price target for IDXX is $228.00 and the low price target for IDXX is $200.00. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Hold|
|Consensus Rating Score: ||2.71||2.67||2.67||2.33|
|Ratings Breakdown: ||1 Sell Rating(s)|
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
|2 Sell Rating(s)|
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$216.50||$198.1667||$190.6667||$171.60|
|Price Target Upside: ||5.00% downside||6.61% downside||0.96% downside||7.45% upside|
IDEXX Laboratories (NASDAQ:IDXX) Consensus Price Target History
IDEXX Laboratories (NASDAQ:IDXX) Analyst Ratings History
(Data available from 6/17/2016 forward)
IDEXX Laboratories (NASDAQ:IDXX) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
IDEXX Laboratories (NASDAQ IDXX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.56%
Institutional Ownership Percentage: 86.31%
IDEXX Laboratories (NASDAQ IDXX) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|5/30/2018||Jacqueline Studer||VP||Sell||475||$209.98||$99,740.50|| |
|5/29/2018||Giovani Twigge||Insider||Sell||1,626||$204.37||$332,305.62|| |
|5/10/2018||William T End||Director||Sell||9,470||$208.36||$1,973,169.20||31,786|| |
|2/28/2018||Daniel M Junius||Director||Sell||2,974||$190.06||$565,238.44||5,602|| |
|2/22/2018||William T End||Director||Sell||4,000||$184.48||$737,920.00||41,256|| |
|2/14/2018||Lawrence D Kingsley||Director||Buy||1,000||$178.05||$178,050.00||4,558|| |
|2/8/2018||Jonathan W Ayers||Chairman||Sell||22,000||$177.52||$3,905,440.00||1,077,112|| |
|2/7/2018||Bruce L Claflin||Director||Buy||1,000||$179.58||$179,580.00||1,000|| |
|2/6/2018||Jonathan W Ayers||Chairman||Sell||36,000||$179.28||$6,454,080.00||1,077,112|| |
|2/5/2018||Brian P Mckeon||VP||Sell||6,602||$181.36||$1,197,338.72||47,040|| |
|1/11/2018||Jonathan W Ayers||CEO||Sell||2,160||$167.03||$360,784.80||1,077,112|| |
|1/9/2018||Jonathan W Ayers||CEO||Sell||18,000||$165.15||$2,972,700.00||1,077,112|| |
|11/30/2017||Giovani Twigge||Insider||Sell||2,000||$156.07||$312,140.00|| |
|11/16/2017||Jonathan W Ayers||CEO||Sell||18,000||$153.61||$2,764,980.00||1,064,573|| |
|11/14/2017||Jonathan W Ayers||CEO||Sell||18,000||$148.35||$2,670,300.00||1,064,573|| |
|11/7/2017||Jonathan W Ayers||Chairman||Sell||54,000||$151.32||$8,171,280.00||1,064,573|| |
|11/3/2017||Jonathan W Ayers||CEO||Sell||18,000||$153.75||$2,767,500.00||1,064,573|| |
|8/28/2017||Jonathan W Ayers||Chairman||Sell||13,000||$150.79||$1,960,270.00||1,044,034|| |
|8/23/2017||Rebecca M Henderson||Director||Sell||5,156||$153.29||$790,363.24||17,274|| |
|8/22/2017||Rebecca M Henderson||Director||Sell||2,578||$152.86||$394,073.08||17,274|| |
|8/16/2017||Jonathan W Ayers||Chairman||Sell||58,000||$155.00||$8,990,000.00||1,043,034|| |
|8/15/2017||Jonathan W Ayers||CEO||Sell||20,000||$154.62||$3,092,400.00||1,043,034|| |
|8/14/2017||Jonathan W Ayers||CEO||Sell||18,000||$154.91||$2,788,380.00||1,043,034|| |
|8/9/2017||Jonathan W Ayers||Chairman||Sell||17,000||$154.54||$2,627,180.00||1,039,034|| |
|8/8/2017||Jonathan W. Ayers||Chairman||Sell||18,000||$155.22||$2,793,960.00|| |
|8/3/2017||Lawrence D Kingsley||Director||Buy||2,000||$151.76||$303,520.00||3,344|| |
|5/31/2017||Giovani Twigge||Insider||Sell||2,572||$166.90||$429,266.80|| |
|5/30/2017||Jonathan W Ayers||Chairman||Sell||13,000||$167.82||$2,181,660.00||1,032,994|| |
|5/22/2017||William T End||Director||Sell||5,000||$162.55||$812,750.00||45,256|| |
|5/10/2017||Jonathan W Ayers||Chairman||Sell||27,000||$162.69||$4,392,630.00||1,024,994|| |
|5/5/2017||Jonathan W. Ayers||Chairman||Sell||26,000||$160.61||$4,175,860.00|| |
|5/4/2017||Rebecca M Henderson||Director||Sell||1,700||$159.95||$271,915.00||21,552|| |
|3/1/2017||Lawrence D Kingsley||Director||Buy||1,000||$146.48||$146,480.00||1,135|| |
|2/22/2017||Jonathan W Ayers||Chairman||Sell||35,000||$142.58||$4,990,300.00||995,947|| |
|2/8/2017||Brian P Mckeon||VP||Sell||9,924||$141.64||$1,405,635.36||45,235|| |
|2/8/2017||Daniel M Junius||Director||Sell||3,000||$141.75||$425,250.00||5,495|| |
|2/8/2017||Jonathan W. Ayers||Chairman||Sell||36,250||$141.63||$5,134,087.50|| |
|11/29/2016||Jonathan W Ayers||Chairman||Sell||27,424||$119.77||$3,284,572.48||1,001,043|| |
|11/28/2016||Jonathan W Ayers||CEO||Sell||13,188||$119.57||$1,576,889.16||1,001,043|| |
|11/23/2016||Thomas Craig||Director||Sell||8,500||$120.06||$1,020,510.00||32,783|| |
|11/9/2016||Jonathan W. Ayers||Chairman||Sell||40,000||$107.85||$4,314,000.00|| |
|11/8/2016||William T End||Director||Sell||5,000||$109.87||$549,350.00||48,654|| |
|8/25/2016||Rebecca M Henderson||Director||Sell||9,924||$110.43||$1,095,907.32||16,678|| |
|8/15/2016||Barry C Johnson||Director||Sell||9,924||$111.37||$1,105,235.88||13,484|| |
|8/8/2016||Michael J. Phd Williams||Insider||Sell||49,560||$108.94||$5,399,066.40|| |
|8/5/2016||William T End||Director||Sell||5,000||$108.50||$542,500.00||53,564|| |
|8/4/2016||Jonathan W. Ayers||Chairman||Sell||60,000||$107.69||$6,461,400.00|| |
|5/5/2016||William T End||Director||Sell||4,924||$85.87||$422,823.88||63,578|| |
|2/24/2016||Michael J Phd Williams||EVP||Sell||2,000||$71.93||$143,860.00||40,011|| |
|2/9/2016||Thomas Craig||Director||Sell||2,054||$69.52||$142,794.08||22,298|| |
|2/8/2016||Brian P. Mckeon||CFO||Sell||9,054||$69.65||$630,611.10||32,461|| |
|11/30/2015||Thomas Craig||Director||Sell||7,000||$70.28||$491,960.00||22,048|| |
|11/12/2015||Rebecca M. Henderson||Director||Sell||2,300||$68.39||$157,297.00||21,450|| |
|8/31/2015||Thomas Craig||Director||Sell||800||$71.77||$57,416.00||21,793|| |
|8/18/2015||Michael J. Phd Williams||EVP||Sell||6,586||$78.34||$515,947.24||39,654|| |
|8/18/2015||Thomas Craig||Director||Sell||2,900||$79.41||$230,289.00||22,593|| |
|8/17/2015||Jonathan W Ayers||CEO||Sell||14,799||$78.45||$1,160,981.55|| |
|5/18/2015||William T End||Director||Sell||3,527||$134.51||$474,416.77|| |
|3/10/2015||William T End||Director||Sell||3,500||$150.89||$528,115.00|| |
|3/4/2015||Johnny D Powers||EVP||Sell||6,168||$158.49||$977,566.32|| |
|2/17/2015||Brian P Mckeon||CFO||Sell||5,000||$156.99||$784,950.00|| |
|2/12/2015||Jonathan W Ayers||CEO||Sell||58,245||$155.45||$9,054,185.25|| |
|2/5/2015||Rebecca M Henderson||Director||Sell||2,934||$156.27||$458,496.18|| |
|2/4/2015||Thomas Craig||Director||Sell||2,200||$157.02||$345,444.00|| |
|1/14/2015||Jonathan W Ayers||CEO||Sell||28,512||$157.68||$4,495,772.16|| |
|12/3/2014||Jonathan W Ayers||CEO||Sell||29,000||$148.49||$4,306,210.00|| |
|11/13/2014||Thomas Craig||Director||Sell||5,000||$152.45||$762,250.00|| |
|11/5/2014||Jonathan W Ayers||CEO||Sell||29,000||$143.45||$4,160,050.00|| |
|11/4/2014||Johnny D Powers||EVP||Sell||1,292||$142.70||$184,368.40|| |
|8/13/2014||M Anne Szostak||Director||Buy||2,000||$127.03||$254,060.00|| |
|2/20/2014||M Anne Szostak||Director||Buy||2,000||$126.71||$253,420.00||5,000|| |
|2/19/2014||Thomas Craig||Director||Sell||4,800||$125.42||$602,016.00||11,976|| |
|2/3/2014||Jonathan Ayers||CEO||Sell||81,294||$112.46||$9,142,323.24||389,665|| |
|11/26/2013||Jonathan Ayers||CEO||Sell||78,178||$105.29||$8,231,361.62||377,211|| |
|11/22/2013||Sophie Vandebroek||Director||Buy||1,000||$107.84||$107,840.00||1,000|| |
|11/13/2013||Jonathan Ayers||CEO||Sell||78,178||$106.36||$8,315,012.08||365,389|| |
|11/4/2013||M Anne Szostak||Director||Buy||1,000||$108.24||$108,240.00||3,000|| |
|11/4/2013||Michael Phd Williams||EVP||Sell||6,020||$108.19||$651,303.80||11,566|| |
|10/31/2013||William T End||Director||Sell||2,500||$108.32||$270,800.00|| |
|10/25/2013||Jonathan W Ayers||CEO||Sell||78,178||$104.36||$8,158,656.08|| |
|9/13/2013||Johnny Powers||EVP||Sell||13,128||$96.59||$1,268,033.52||8,989|| |
|9/5/2013||Michael J Phd Williams||EVP||Sell||5,162||$95.58||$493,383.96|| |
|5/9/2013||Ali Naqui||VP||Sell||12,961||$87.00||$1,127,607.00|| |
|2/4/2013||Merilee Raines||CFO||Sell||175,929||$94.25||$16,581,308.25|| |
|11/13/2012||Jonathan W Ayers||CEO||Sell||15,000||$89.92||$1,348,800.00|| |
|9/5/2012||Johnny D Powers||EVP||Sell||4,000||$97.12||$388,480.00|| |
|8/8/2012||Merilee Raines||CFO||Sell||7,726||$88.84||$686,377.84|| |
IDEXX Laboratories (NASDAQ IDXX) News Headlines
IDEXX Laboratories (NASDAQ:IDXX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
IDEXX Laboratories (NASDAQ:IDXX) Income Statement, Balance Sheet and Cash Flow Statement
IDEXX Laboratories (NASDAQ IDXX) Stock Chart for Sunday, June, 17, 2018